Navigation Links
Treating patients with psychiatric disorders for hepatitis C
Date:12/3/2007

People with severe mental illnesses are far more likely to be infected with Hepatitis C virus compared to the general population, however, they often do not get treatment for their liver disease because current antiviral therapies have known psychiatric side effects.

Against this epidemiological background, the article by Schaefer and colleagues, Hepatitis C treatment in psychiatric risk patients, represents an important study in the field, write Sanjeev Arora and Cynthia Geppert, in the December issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). Their editorial is also available online at Wiley Interscience (http://www.interscience.wiley.com/journal/hepatology).

It provides an even stronger empirical foundation for the findings of other less methodologically rigorous studies showing that patients with HCV and comorbid psychiatric and substance use disorders have comparable sustained viral responses (SVR) and rates of depression when treated with antiviral therapies, Arora and Geppert report.

While the National Institutes of Health once advised doctors against treating HCV-infected patients who continued to use illicit drugs, drink alcohol, or who had a psychiatric history, in 2002, the agency released a statement that said efforts should be made to increase the availability of the best current treatments to those patients.

Research has shown this approach to be feasible and effective, and it also has important implications for public health. Still, doctors have been slow to act on the recommendation.

Arora and Geppert applaud Shaefer et. als work with very difficult to treat patients and point out that the key to their success was the use of a multidisciplinary team. The patients in this study were carefully screened and monitored and received extensive education and counseling, they point out. They also praise the work because it assessed both depressive and psychotic symptoms and demonstrates that neither diagnosis adversely affected SVR or outcome. Instead, the study adds to the growing body of evidence that shows using anti-depressant agents prior to and during HCV treatment can lessen, or even prevent, depressive reactions.

While Arora and Geppert point out that the small sample size in Schaefer et. als study means that the conclusion that there is no difference in SVR between controls and patients with mental health diagnosis is stronger than the data can support, they praise the forward-thinking nature of the work.

The value of Schaefer et al.s work is precisely in contributing to the growing body of data that challenge hepatologists and mental health professionals to develop new medications and innovative programs that can further widen the door to admit these patients to HCV treatment, the authors conclude.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
2. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
3. Treating diabetes during pregnancy can break link to childhood obesity
4. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
5. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
6. Family-based treatment more effective than supportive psychotherapy in treating bulimia
7. Treating depression may improve recovery of heart rate variability following coronary syndromes
8. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
9. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
10. Stem cells show promise for treating Huntingtons disease
11. Treating obstructive sleep apnea, preventing heart attacks and strokes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... The Fertility Centers of ... a Cigna Infertility Center of Excellence. The Cigna Center of Excellence recognizes participating ... honor to be designated a Cigna Infertility Center of Excellence," said Fertility Centers ...
(Date:11/30/2016)... , ... November 30, 2016 , ... "I hate when ... arm while brushing my teeth," said an inventor from Bridgewater, N.J. "I thought that ... develop this handy device." , He developed the patent-pending DEFLECTOR to prevent saliva and ...
(Date:11/30/2016)... Palm Beach Gardens, FL (PRWEB) , ... November ... ... leader in eating disorder and mental health treatment has announced the opening of ... facility provides specialized partial hospitalization and intensive outpatient treatment for adults and adolescents, ...
(Date:11/30/2016)... ... November 30, 2016 , ... In ... been a focus of public policymakers and system stakeholders in many states. To ... its Medical Price Index for Workers’ Compensation, Eighth Edition (MPI-WC) . , ...
(Date:11/30/2016)... ... 2016 , ... The Clinical Data Interchange Standards Consortium (CDISC) ... goes into effect next month. Sponsors whose studies start after December 17, 2016 ... The current FDA Data Standards Catalog specifies the use of CDISC standards: ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 On Thursday, the NASDAQ Composite ... while the Dow Jones Industrial Average managed to stay in ... markets, which prompted Stock-callers this morning to look at the ... NUVA ), Smith & Nephew PLC (NYSE: ... and Cesca Therapeutics Inc. (NASDAQ: KOOL ). You ...
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... , Dec. 2, 2016 Allergan plc (NYSE: ... provided additional information on its previously announced Accelerated Share Repurchase ... ... As previously announced, the Company entered ... under which the Company will repurchase $10 billion of its ...
Breaking Medicine Technology: